Tenaya Therapeutics Inc (TNYA)
4.68
+0.06
(+1.30%)
USD |
NASDAQ |
May 03, 16:00
4.68
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Cash from Operations (TTM): -102.07M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -102.07M |
| September 30, 2023 | -102.83M |
| June 30, 2023 | -106.75M |
| March 31, 2023 | -105.96M |
| December 31, 2022 | -104.42M |
| September 30, 2022 | -98.09M |
| June 30, 2022 | -87.19M |
| Date | Value |
|---|---|
| March 31, 2022 | -73.78M |
| December 31, 2021 | -60.81M |
| September 30, 2021 | -54.87M |
| June 30, 2021 | -47.74M |
| March 31, 2021 | -43.00M |
| December 31, 2020 | -35.45M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-106.75M
Minimum
Jun 2023
-35.45M
Maximum
Dec 2020
-78.69M
Average
-87.19M
Median
Jun 2022
Cash from Operations (TTM) Benchmarks
| Adverum Biotechnologies Inc | -90.90M |
| Solid Biosciences Inc | -94.18M |
| Dyne Therapeutics Inc | -219.79M |
| Sana Biotechnology Inc | -253.58M |
| Prime Medicine Inc | -165.41M |